Comparative Pharmacology
Head-to-head clinical analysis: DANOCRINE versus HALOTESTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANOCRINE versus HALOTESTIN.
DANOCRINE vs HALOTESTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Danazol is a synthetic androgen derived from ethisterone. It suppresses the pituitary-ovarian axis by inhibiting gonadotropin (LH and FSH) release, leading to anovulation and amenorrhea. It also binds to androgen, progesterone, and glucocorticoid receptors, exerting weak androgenic, antiestrogenic, and antigonadotropic effects. Additionally, it may directly inhibit ovarian steroidogenesis and increase clearance of endogenous sex hormones.
Fluoxymesterone is a synthetic androgen that binds to androgen receptors, activating gene transcription and promoting protein synthesis, leading to anabolic and androgenic effects.
100-200 mg orally twice daily for endometriosis; 200-400 mg twice daily for fibrocystic breast disease; 200 mg twice daily for hereditary angioedema. Maximum dose: 800 mg/day.
10-20 mg orally three to four times daily for replacement therapy; 2-10 mg orally daily for delayed puberty in males.
None Documented
None Documented
Terminal elimination half-life: 10–30 hours (mean 15 hours); clinically, steady-state reached after 2–4 days.
Terminal elimination half-life: 9.6 hours. Clinical context: Steady-state achieved after ~48 hours.
Renal (metabolites, ~50%), biliary/fecal (~30%), unchanged drug minimal.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%.
Category C
Category C
Androgen/Antigonadotropin
Androgen